Emilio Porfiri

5.6k total citations · 2 hit papers
69 papers, 3.8k citations indexed

About

Emilio Porfiri is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Emilio Porfiri has authored 69 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 29 papers in Molecular Biology and 29 papers in Oncology. Recurrent topics in Emilio Porfiri's work include Renal cell carcinoma treatment (21 papers), Cancer Genomics and Diagnostics (14 papers) and Prostate Cancer Treatment and Research (11 papers). Emilio Porfiri is often cited by papers focused on Renal cell carcinoma treatment (21 papers), Cancer Genomics and Diagnostics (14 papers) and Prostate Cancer Treatment and Research (11 papers). Emilio Porfiri collaborates with scholars based in United Kingdom, Italy and United States. Emilio Porfiri's co-authors include Paul Polakis, Iris Albert, Bonnee Rubinfeld, S Munemitsu, Carol J. Fiol, Mona El‐Gamil, Paul F. Robbins, John F. Hancock, Frank McCormick and Timothy A. Evans and has published in prestigious journals such as Science, Journal of Biological Chemistry and Nature Genetics.

In The Last Decade

Emilio Porfiri

69 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly

1996 1.2k citations Bonnee Rubinfeld, Iris Albert et al. Science profile →
Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines

1997 1.1k citations Bonnee Rubinfeld, Paul F. Robbins et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emilio Porfiri United Kingdom	22	2.9k	846	547	506	419	69	3.8k
Jim Heighway United Kingdom	32	2.3k 0.8×	1.6k 1.9×	329 0.6×	655 1.3×	498 1.2×	72	3.4k
Egle Avizienyte United Kingdom	24	1.8k 0.6×	913 1.1×	541 1.0×	235 0.5×	926 2.2×	34	3.0k
Jonathan M. Yingling United States	26	2.7k 0.9×	1.3k 1.5×	330 0.6×	502 1.0×	129 0.3×	49	3.6k
Mark A. Pershouse United States	15	2.4k 0.8×	615 0.7×	433 0.8×	330 0.7×	308 0.7×	33	3.1k
Torben F. Ørntoft Denmark	13	2.5k 0.9×	1.5k 1.8×	702 1.3×	269 0.5×	338 0.8×	20	3.6k
Alessia Ciarrocchi Italy	33	2.4k 0.8×	1.2k 1.4×	272 0.5×	639 1.3×	302 0.7×	115	4.0k
Belinda Cancilla United States	18	1.5k 0.5×	1.1k 1.4×	309 0.6×	673 1.3×	171 0.4×	38	2.7k
Tokuzo Arao Japan	38	2.2k 0.8×	1.4k 1.7×	326 0.6×	1.1k 2.1×	320 0.8×	90	3.7k
Frederic Tort Spain	19	2.6k 0.9×	1.3k 1.6×	461 0.8×	219 0.4×	360 0.9×	38	3.4k
David Sarrió Spain	28	2.6k 0.9×	2.0k 2.4×	543 1.0×	478 0.9×	391 0.9×	37	4.5k

Countries citing papers authored by Emilio Porfiri

Since Specialization

Citations

This map shows the geographic impact of Emilio Porfiri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emilio Porfiri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emilio Porfiri more than expected).

Fields of papers citing papers by Emilio Porfiri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emilio Porfiri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emilio Porfiri. The network helps show where Emilio Porfiri may publish in the future.

Co-authorship network of co-authors of Emilio Porfiri

This figure shows the co-authorship network connecting the top 25 collaborators of Emilio Porfiri. A scholar is included among the top collaborators of Emilio Porfiri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emilio Porfiri. Emilio Porfiri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Zarkar, Anjali, Sarah Pirrie, Clive Stubbs, et al.. (2022). A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial. Clinical Genitourinary Cancer. 20(5). 473–481. 2 indexed citations

2.

Wragg, Joseph W., Jane Anderson, Henry J.M. Ferguson, et al.. (2016). MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome. Cancer Research. 76(8). 2314–2326. 53 indexed citations

3.

Rao, Ankit, et al.. (2016). An Unusual Cause of Subacute Headache in a Patient Undergoing Chemotherapy for Advanced Testicular Nonseminomatous Germ Cell Tumour. Case Reports in Oncological Medicine. 2016. 1–3. 3 indexed citations

4.

Rao, Ankit & Emilio Porfiri. (2015). Cerebrovascular Ischemic Events in Patients With Advanced Renal Cell Carcinoma Treated With Anti-Angiogenic Tyrosine Kinase Inhibitors: A Report on Two Cases With Different Outcomes. Journal of Medical Cases. 6(10). 463–467. 1 indexed citations

5.

Wagstaff, John, Robert J. Jones, Robert D. Hawkins, et al.. (2015). Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of Oncology. 27(1). 159–165. 33 indexed citations

6.

Caldarella, Carmelo, Barbara Muoio, Maria Antonietta Isgrò, et al.. (2013). The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiology and Oncology. 48(3). 219–227. 26 indexed citations

7.

Loreto, Carla Di, Fabio Puglisi, Paul G. Murray, et al.. (2012). Thymidine phosphorylase expression in metastatic kidney cancer as a potential predictor of outcome in patients treated with sunitinib.. Journal of Clinical Oncology. 30(15_suppl). e15091–e15091. 2 indexed citations

8.

Porfiri, Emilio, et al.. (2011). Sunitinib-induced Acute Psychosis: Case Report. Clinical Genitourinary Cancer. 9(1). 70–72. 8 indexed citations

9.

Nathan, Paul, John Wagstaff, Emilio Porfiri, Tom Powles, & Tim Eisen. (2009). UK guidelines for the systemic treatment of renal cell carcinoma. British Journal of Hospital Medicine. 70(5). 284–286. 6 indexed citations

10.

Bianchi, Francesca, Gennaro Galizia, R. Bracci, et al.. (2007). Effectiveness of the crcapro program in identifying patients suspected for HNPCC. Clinical Genetics. 71(2). 158–164. 8 indexed citations

11.

Bianchi, Francesca, Laura Belvederesi, Cristian Loretelli, et al.. (2006). MSH2 splice site mutation and endometrial cancer. International Journal of Gynecological Cancer. 16(3). 1419–1423. 2 indexed citations

12.

Bianchi, Francesca, Laura Belvederesi, Cristian Loretelli, et al.. (2006). MSH2 splice site mutation and endometrial cancer. International Journal of Gynecological Cancer. 16(3). 1419–1423. 7 indexed citations

13.

Piga, Andrea, Rosaria Gesuita, Vincenzo Catalano, et al.. (2005). Identification of Clinical Prognostic Factors in Patients with Unknown Primary Tumors Treated with a Platinum-Based Combination. Oncology. 69(2). 135–144. 8 indexed citations

14.

Rubinfeld, Bonnee, Paul F. Robbins, Mona El‐Gamil, et al.. (1997). Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines. Science. 275(5307). 1790–1792. 1061 indexed citations breakdown →

15.

Porfiri, Emilio. (1995). DCC (Deleted in Colorectal Cancer) Inactivation in Hematological Malignancies. Leukemia & lymphoma. 18(1-2). 69–72. 11 indexed citations

16.

Porfiri, Emilio, et al.. (1995). [2] Purification of baculovirus-expressed recombinant ras and rap proteins. Methods in enzymology on CD-ROM/Methods in enzymology. 255. 13–21. 27 indexed citations

17.

Porfiri, Emilio, Timothy A. Evans, Pierre Teilhard de Chardin, & John F. Hancock. (1994). Prenylation of Ras proteins is required for efficient hSOS1-promoted guanine nucleotide exchange.. Journal of Biological Chemistry. 269(36). 22672–22677. 106 indexed citations

18.

Porfiri, Emilio, LM Secker-Walker, A. V. Hoffbrand, & John F. Hancock. (1993). DCC tumor suppressor gene is inactivated in hematologic malignancies showing monosomy 18. Blood. 81(10). 2696–2701. 38 indexed citations

19.

Porfiri, Emilio, et al.. (1992). Impaired degradation of Ca(2+)-regulating second messengers in myeloid leukemia cells. Implications for the regulation of leukemia cell proliferation.. PubMed. 6(8). 801–5. 5 indexed citations

20.

Porfiri, Emilio, et al.. (1988). Granulocytic differentiation of HL60 human promyelocytic leukemia cells is preceded by a reduction in levels of inositol lipid-derived second messengers.. PubMed. 16(7). 641–6. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact